ZDI-CAN-28885: ZDI-26-555: Parallels RAS Client RDP Backend Service Exposed Dangerous Function Local Privilege Escalation Vulnerability
This vulnerability allows local attackers to escalate privileges on affected installations of Parallels RAS Client. An attacker must first obtain the ability to execute low-privileged code on the target system in order to exploit this vulnerability. The specific flaw exists within the RAS RDP Backend Service. The issue results from an exposed dangerous function. An attacker can leverage this vulnerability to escalate privileges and execute arbitrary code in the context of SYSTEM.
Other sources
This vulnerability allows local attackers to escalate privileges on affected installations of Parallels RAS Client. An attacker must first obtain the ability to execute low-privileged code on the target system in order to exploit this vulnerability. The ZDI has assigned a CVSS rating of 7.8. The following CVEs are assigned: CVE-2026-18262.
— ZDI
Affected Software
Remediation
Recommended actions to resolve this vulnerability, in priority order.
- Upgrade
Upgrade
Parallels RAS Client (RDP Backend Service)to a version that resolves this vulnerability.Patch ZDI-26-555 - Upgrade
Upgrade to a fixed release to a version that resolves this vulnerability.
Patch CVE-2026-18262
Event History
Frequently Asked Questions
What is the severity of ZDI-CAN-28885?
The severity of ZDI-CAN-28885 is rated at 7.8 according to the CVSS.
How do I fix ZDI-CAN-28885?
To fix ZDI-CAN-28885, ensure that you update to the latest version of Parallels RAS Client that addresses this vulnerability.
Who is affected by ZDI-CAN-28885?
Users and organizations using affected versions of Parallels RAS Client are at risk from ZDI-CAN-28885.
What type of vulnerability is ZDI-CAN-28885?
ZDI-CAN-28885 is classified as a local privilege escalation vulnerability.
What must an attacker do to exploit ZDI-CAN-28885?
An attacker must first obtain the ability to execute low-privileged code on the target system in order to exploit ZDI-CAN-28885.